Related Experiment Videos
Prevention of sudden cardiac death: the ICD, or an electrical end-point with preceding opportunities for
1Department of Cardiology, Austin Hospital, Melbourne, Vic.
Insights
Sudden cardiac death (SCD) prevention requires a multifaceted approach, including managing coronary artery disease (CAD) and myocardial infarction (MI). Therapies like thrombolysis, aspirin, and beta-blockers can reduce ventricular arrhythmias and SCD risk.
Area of Science:
- Cardiology
- Electrophysiology
- Preventive Medicine
Background:
- Sudden cardiac death (SCD) is primarily caused by ventricular arrhythmias, often linked to advanced structural heart disease, particularly coronary artery disease (CAD).
- The implantable cardioverter-defibrillator (ICD) is a key intervention for SCD survivors, but its use requires careful electrophysiology study guidance.
- Effective prevention of a first cardiac arrest necessitates a comprehensive strategy beyond ICDs, encompassing primary prevention and managing conditions like myocardial infarction (MI).
Purpose of the Study:
- To review the current understanding of sudden cardiac death (SCD) causes and management strategies.
- To emphasize the importance of a multifaceted approach to preventing cardiac arrest, including primary prevention and post-myocardial infarction (MI) therapies.
- To discuss the role of implantable cardioverter-defibrillators (ICDs) and other pharmacological interventions in managing ventricular arrhythmias and reducing SCD risk.
Main Methods:
- Review of existing clinical trials and guidelines concerning sudden cardiac death (SCD), coronary artery disease (CAD), and myocardial infarction (MI).
- Analysis of the efficacy of various therapeutic interventions, including thrombolysis, aspirin, beta-blockers, ACE inhibitors, amiodarone, and ICDs.
- Evaluation of patient stratification based on ejection fraction for determining appropriate treatment strategies, including heart transplantation.
Main Results:
- Effective thrombolysis during myocardial infarction (MI) may positively impact long-term arrhythmic endpoints.
- Post-MI, ventricular arrhythmias and SCD risk can be reduced by medications such as aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and amiodarone.
- For patients with severely reduced ejection fraction (<35%), particularly <15-20%, heart transplantation may be a preferred option over ICDs, alongside heart failure management.
Conclusions:
- Preventing sudden cardiac death (SCD) requires a comprehensive strategy addressing underlying structural heart disease, such as coronary artery disease (CAD), and implementing effective post-myocardial infarction (MI) care.
- Pharmacological therapies and lifestyle modifications play a crucial role in reducing the incidence of ventricular arrhythmias and SCD.
- Individualized treatment decisions, considering ejection fraction and patient-specific factors, are essential for optimizing outcomes in patients at risk for SCD, with ICDs and transplantation being important therapeutic options.
Abstract:
Sudden cardiac death (SCD) is usually due to monomorphic ventricular tachycardia and/or ventricular fibrillation. However, in the vast majority of patients these arrhythmias are associated with advanced structural disease. In our society, this is usually due to coronary artery disease (CAD). The implantable cardioverter--defibrillator is the logical approach to management in survivors of SCD. Its rational use must be guided by electrophysiology study. However, a realistic and cost-effective approach to the prevention of a first cardiac arrest must be multifaceted and take cognisance of other aspects including primary prevention. Limitation of the size of myocardial infarction (MI) is vital. Trials already suggests that effective thrombolysis may impinge long-term on arrhythmic end-points. Following infarction, ventricular arrhythmias and sudden death may also be decreased by aspirin, beta-blockers, and possibly angiotensin converting enzyme inhibitors and amiodarone. Many post-infarction studies employ a combined end-point of death and clinical arrhythmias. However, death is usually confined to those with an ejection fraction < 35%. In them, treatment of associated heart failure is often a consideration and if the ejection fraction < 15-20%, depending on donor availability, transplantation may even be the preferred therapeutic option to the cardioverter-defibrillator.